Anemia News and Research

RSS

Anemia is a decrease in normal number of red blood cells (RBCs) or less than the normal quantity of hemoglobin in the blood. However, it can include decreased oxygen-binding ability of each hemoglobin molecule due to deformity or lack in numerical development as in some other types of hemoglobin deficiency. The three main classes of anemia include excessive blood loss (acutely such as a hemorrhage or chronically through low-volume loss), excessive blood cell destruction (hemolysis) or deficient red blood cell production (ineffective hematopoiesis). Anemia is the most common disorder of the blood. There are several kinds of anemia, produced by a variety of underlying causes. Anemia can be classified in a variety of ways, based on the morphology of RBCs, underlying etiologic mechanisms, and discernible clinical spectra, to mention a few.

Alnylam second quarter revenue decreases to $20.6 million

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, today reported its consolidated financial results for the second quarter 2011, and company highlights.

From Precision NanoSystems Inc. 2 Aug 2011

Positive results from Alnylam's ALN-VSP Phase I trial for liver cancer

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has completed its Phase I study with ALN-VSP, a systemically delivered RNAi therapeutic for the treatment of advanced solid tumors with liver involvement.

1 Aug 2011

Colon cleansing can cause side effects like cramping, renal failure and death

Colon cleansing - it's been described as a natural way to enhance well-being, but Georgetown University doctors say there's no evidence to back that claim. In fact, their review of scientific literature, published today in the August issue of The Journal of Family Practice, demonstrates that colon cleansing can cause side effects ranging from cramping to renal failure and death.

1 Aug 2011

EGT transfers clinical grade lentiviral vector to MSKCC

Errant Gene Therapeutics, LLC, a pioneering boutique drug development firm specializing in Rare Diseases, announced the transfer of its clinical grade lentiviral vector, TNS 9.55.3, to Memorial Sloan Kettering Cancer Center.

29 Jul 2011

BTI's IPOXYN data on traumatic shock and ischemia to be presented at XIIIth MGH symposium

Boston Therapeutics, Inc., a public company registered with the SEC and a developer of diabetes therapeutics, announced today that experiments performed in the laboratory of Massachusetts General Hospital (MGH) faculty member Warren M. Zapol, MD, Emeritus Anesthetist-in-Chief and Director of the MGH Anesthesia Center for Critical Care Research, on BTI's new oxygen carrier for traumatic shock and ischemia, IPOXYNTM, will be presented at the "XIII International Symposium on Blood Substitutes and Oxygen Therapeutics" to be held July 27th-29th at MGH.

29 Jul 2011

Celgene reports second quarter total revenue of $1.18 billion

Celgene Corporation announced non-GAAP net income of $417 million, or non-GAAP diluted earnings per share of $0.89, for the quarter ended June 30, 2011. Non-GAAP net income for the second quarter of 2010 was $323 million, or non-GAAP diluted earnings per share of $0.69.

28 Jul 2011

FDA accepts peginesatide NDA for anemia associated with CKD

Affymax, Inc. and Takeda Global Research & Development Center, Inc., U.S., today announced that the U.S. Food and Drug Administration (FDA) accepted for review the New Drug Application (NDA) for peginesatide (formerly known as Hematide™) for the treatment of anemia associated with chronic kidney disease (CKD) in adult patients on dialysis.

27 Jul 2011

Positive data from two GSK's Promacta Phase III studies on hepatitis C-related thrombocytopenia

Ligand Pharmaceuticals Incorporated today announced that its partner GlaxoSmithKline has announced that it received positive data from ENABLE-1, the first of two Phase III studies examining Promacta in patients with hepatitis C-related thrombocytopenia, and that full data will be released at an upcoming scientific conference.

27 Jul 2011

'Core-shell' nanoparticles for effective intracellular delivery of RNAi therapeutics

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, together with collaborators at the Massachusetts Institute of Technology (MIT), announced today the publication of new paper describing discovery of "core-shell" nanoparticles for systemic delivery of RNAi therapeutics.

26 Jul 2011

Fluoride supplements neither safe or effective

Sodium fluoride supplements "have not been found by FDA to be safe or effective," according to the U.S. National Library of Medicine's website, reports the New York State Coalition Opposed to Fluoridation, Inc..

25 Jul 2011

Baxter GAMMAGARD LIQUID for PI receives FDA approval for subcutaneous administration

Baxter International Inc. announced today that the U.S. Food and Drug Administration has approved the subcutaneous administration of GAMMAGARD LIQUID 10% [Immune Globulin Infusion (Human)] for patients with primary immunodeficiency.

From Baxter International Inc. 25 Jul 2011

FDA approves Cephalon's REMS for FENTORA, ACTIQ

Cephalon, Inc. announced today that the U.S. Food and Drug Administration (FDA) approved the Risk Evaluation and Mitigation Strategy (REMS) for FENTORA and ACTIQ.

22 Jul 2011

Researchers discover novel combination of two mutations in a patient with ADHD

Often enough, in science as in life, unexpected knowledge has a personal impact. Researchers seeking rare gene variants in just a few individuals with attention-deficit hyperactivity disorder (ADHD) discovered that one patient had a novel combination of two mutations.

21 Jul 2011

Essential criteria for clinical diagnosis of restless legs syndrome

We've all experienced abnormal sensations in our legs at one time or another, but for as many as 10 percent of the US population, restless legs syndrome (RLS) is a daily occurrence. Characterized by throbbing, pulling, tingling, itching, and crawling sensations, RLS is a neurological disorder that produces unpleasant physical sensations in the extremities and an urge to counteract that sensation by movement.

21 Jul 2011

Roche, Merck sign new non-exclusive agreement for HCV triple combination therapy

Merck, known as MSD outside the United States and Canada, announced today that it has signed a new non-exclusive agreement with Roche, through the companies' respective subsidiaries, for the global promotion, upon appropriate marketing approvals, of VICTRELIS (boceprevir) as part of a triple combination therapy regimen with peginterferon alfa and ribavirin.

21 Jul 2011

AMAG enters definitive merger agreement with Allos Therapeutics

AMAG Pharmaceuticals, Inc. and Allos Therapeutics, Inc. today announced that they have entered into a definitive merger agreement under which the companies will combine in an all-stock merger with a total equity value of approximately $686 million.

21 Jul 2011

Millennium submits VELCADE sNDA to FDA to add OS data for previously untreated multiple myeloma

Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited today announced the submission of a supplemental New Drug Application (sNDA) with the U.S. Food and Drug Administration for VELCADE® (bortezomib) for injection to add overall survival data after a five-year follow up to the product label.

20 Jul 2011

Thalidomide analog shows promise against sickle cell disease

A thalidomide analog is shaping up as a safe, worthy opponent of sickle cell disease, Georgia Health Sciences University researchers report.

19 Jul 2011

Optimer introduces DIFICID for treatment of C. difficile-associated diarrhea

Optimer Pharmaceuticals, Inc. today announced the commercial launch of DIFICID (fidaxomicin) tablets for the treatment of Clostridium difficile-associated diarrhea (CDAD) in patients 18 years of age and older.

19 Jul 2011

Coal seam gas and cancer risk: Report

An Australian Senate committee has been looking into the impact of coal seam gas (CSG) mining on the Murray-Darling Basin that has moved to Dalby on Queensland's western Darling Downs today. The Senate Standing Committee on Rural Affairs and Transport is touring southern Queensland examining the environmental consequences of CSG mining on the Murray-Darling River system.

19 Jul 2011